WO2012010587A1 - Stabilisation du sulforaphane - Google Patents
Stabilisation du sulforaphane Download PDFInfo
- Publication number
- WO2012010587A1 WO2012010587A1 PCT/EP2011/062329 EP2011062329W WO2012010587A1 WO 2012010587 A1 WO2012010587 A1 WO 2012010587A1 EP 2011062329 W EP2011062329 W EP 2011062329W WO 2012010587 A1 WO2012010587 A1 WO 2012010587A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sulforaphane
- free
- compound
- optionally
- ester
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Definitions
- the present invention relates to the field of stabilization of a compound of general formula (I) in which R 1 and R 2 both represent, independently of one another, an alkyl, aryl or arylalkyl group, optionally substituted by one or more heteroatoms, linear or branched,
- the present invention relates to the stabilization of a compound of general formula (I) in which R 1 represents a butyl group and R 2 represents a methyl group, said compound of general formula (I) being sulforaphane.
- Document FR 2888235 discloses a process for stabilizing sulforaphane using acacia gum. This document discloses that sulforaphane is sensitive to light, oxygen, and temperature for the extracted concentrate product.
- Gum acacia or gum arabic has film-forming properties that protect an active ingredient by forming a barrier to oxygen, light and water by matrix encapsulation.
- a sample of natural sulforaphane has been stabilized with different levels of gum acacia.
- samples containing 50% and 70% of acacia gum, respectively sulforaphane content of 36.05% and 22.4% are placed under normal aging conditions (25 ° C. and 60% humidity) and accelerated (40 ° C and 75% humidity). Sulforaphane is dosed over several weeks, allowing to determine the percentage of degradation of the product.
- the sample having 50% of acacia gum does not exhibit any particular stabilization and under accelerated aging conditions, the degradation is twice as great as under normal conditions.
- the sample having a content of 70% gum arabic also shows degradation in both aging conditions but to a lesser extent than the previous sample. In fact, the degradation does not exceed 30% after more than one month at 40 ° C whereas at 25 ° C, there is a slight degradation the first week, then the sulforaphane extract appears relatively stable and does not show increasing the percentage of degradation. In addition, such a quantity of stabilizer leaves no room for other compounds in the production of formulations.
- EP 2120969 also discloses a method for stabilizing sulforaphane which is known as an unstable oil using cyclodextrins. This document does not disclose the origin of the instability of sulforaphane and even proposes to dilute it before contact with a cyciodextrin.
- Cyclodextrins are oiigosaccharides composed of 5 ⁇ or more) ⁇ -D-glucopyranoside units bound in 1 -4 and capable of forming complexes by inclusion of hydrophobic molecules. These can be released under certain conditions by insertion into the cyciodextrin of another molecule.
- cyclodextrins ⁇ , ⁇ and ⁇ which are composed respectively of 6, 7 and 8 molecules of sugar.
- the amount of sulforaphane was determined by HPLC using an internal standard after placing sulforaphane-cyclodextrin complexes under different conditions: sealed samples stored at room temperature or at -30 ° C and open sample conditioned at 40 ° C.
- a suitable medium for diluting the active substance in order to reach the concentration of active substance per unit area of the skin.
- this diluent medium the skilled person generally chooses an aqueous phase, an alcohol or a mixture thereof (the other organic solvents being generally inapplicable to the skin).
- EP 2163238 discloses a very long list of carboxylic acids mixed with sulforaphane or certain derivatives such as sulforaphen to obtain a depigmenting action.
- WO 02/15722 discloses a method for preventing the growth of helicobacter through the use of glucosinolate, isothiocyanate or a derivative thereof.
- the isothiocyanate may be sulforaphane and the disclosed method of treatment involves administering compositions to patients.
- excipients or carriers for such compositions among which are water, solutions, dispersions, suspensions, aqueous or non-aqueous emulsions, sterile powders to be reconstituted.
- This document discloses as examples aqueous or non-aqueous carriers, diluents, solvents or excipients water, ethanol, polyols, carboxymethylcellulose, vegetable oils and injectable organic esters such as ethyl oleate.
- adjuvants such as preservatives, wetting agents, emulsifiers or dispersing agents and antibacterial agents, antifungal agents (parabens, chlorobutanol, phenol, ascorbic acid, etc.) binders, pulverulent particles such as that fillers, adsorption retarding agents, ...
- WO 2008/007728 discloses a coenzyme A preparation in a lipid structure according to the title of the application. A detailed analysis of the document discloses that this document discloses skin care preparations for external use with improved whitening effect of the skin.
- This preparation comprises a hydroquinone glycoside or one of these derivatives as whitening agent, L-ascorbic acid, a placental extract, an alkyl resorcinol, a tranexamic acid and a coenzyme A.
- This document discloses that the whitening agents kojic acid, colloidal sulfur and hydroquinone are degraded in pharmaceutical preparations and their effect is lost.
- This document uses liposomes as a carrier for the whitening agent.
- this document does not mention sulforaphane.
- FR 284318 discloses formulas containing water and glucoraphene or sulforaphane and a UV / IR protection factor and / or antioxidants.
- UVB fi lters are found camphors, benzoic acid, cinnamic, salicylic acid esters, benzophenone derivatives, benzalmalonic acid esters, triazine derivatives or a few others. ketones and alkanes.
- sulfonic acids and their salts are found.
- UVA derivatives, benzoyimethane derivatives, enamine compounds, and photoprotective pigments may be present. also added as metal oxides or their salts (ZnO, TiO 2 , FeO, Fe 2 O 3 , ...), silicates, sulphates or stearates.
- antioxidants called secondary photoprotectors
- amino acids imidazoies, peptides, carotenes or carotenoids
- chlorogenic acid lipoic acid
- propylthiouracil glutathione
- glycosyl esters N-acetyl, methyl, ethyl, etc.
- formulations according to EP 2163238 also contain an alcohol, 1,6-hexanediol, which is also nucleophilic.
- This document therefore discloses formulations which can not be stable and which contain after storage of many degradation products. Moreover no information about the stabilization of sulforaphane is not mentioned in this document, nor as to the degradation of the active substance.
- WO 02/15722 for its part also lists numerous components of various compositions disclosed, in bulk and without details, which are predominantly water-based or are alcohols.
- the sulforaphane or the broccoli extracts containing it are diluted in the culture medium or in a food.
- the media are all of an aqueous, hydrophilic and polar nature, which affects the stability of sulforaphane and rapidly produces degradation products.
- the document FR 2888235 discloses galenic compositions for external use comprising a wide range of additives and always water. Therefore, if the active agent is glucoraphanin, it will remain stable, but if it is sulforaphane, it degrades into thiourea. (Note that in fact, glucoraphanin, if it is more stable, it is inactive). This document does not disclose a solution for stabilizing sulforaphane in a pharmaceutical composition.
- the invention therefore provides a stable pharmaceutical composition of a compound of general formula I in which R 1 and R 2 are, independently of one another, an alkyl, aryl or arylalkyl group. , possibly substituted by one or more linear or branched groups, possibly cyclic, optionally bearing one or more heteroatoms.
- At least one anhydrous ester whose main chain and / or optionally the branched chains are free from free and / or reactive groups or functions in an amount ranging from 0.1 to 99.9% by weight relative to the total weight of the composition cosmetically and pharmaceutically acceptable, and
- composition optionally a cosmetically and pharmaceutically acceptable excipient to complete 100% of the total weight of the composition.
- esters are therefore compatible with the active molecule and are, for example, free of, inter alia, nucleophilic groups.
- Such anhydrous esters free of free and / or reactive groups or functions are also esters such that the process of synthesis or extraction does not induce the presence in the finished product of other products. molecules incompatible with the asset.
- the formulation "at least one anhydrous ester whose main chain and / or optionally the branched chains are free of free and / or reactive groups or functions" also covers a mixture of esters corresponding each to to the above definition, but excluded any mixture or eventual natural extract qualified ester rich or ester mixture but containing a set of other molecules.
- composition according to the invention can be as much a stabilized additive based on a compound of formula (I) which is stable and not degraded over time in an anhydride ester with chains free from free groups or functions and / or as a carrier or a cosmetic or pharmaceutical formulation in which an additional excipient is present.
- This cosmetic and pharmaceutically acceptable excipient must be of non-aqueous, non-nucleophilic, non-hygroscopic, non-hydrated type. More particularly, this cosmetic and pharmaceutical excipient can not be an ester which does not meet the above definition, must be non-hygroscopic, non-hydrated; may not be a surfactant for the purpose of forming emulsions of the aqueous phase / oily phase type, may not comprise free and / or reactive functions within the meaning of what has been defined above, for example (SH, NH 2, NH 3 + ) regardless of the position on the side or main chain so as not to be likely to degrade sulforaphane and thus be able to improve the effectiveness of the composition.
- this cosmetic and pharmaceutical excipient can not be an ester which does not meet the above definition, must be non-hygroscopic, non-hydrated; may not be a surfactant for the purpose of forming emulsions of the aqueous phase / oily phase type, may
- said compound of general formula (I) is sulforaphane, that is to say that R 1 represents a butyl group and R2 a methyl group.
- said cosmetically and pharmaceutically acceptable anhydrous ester is chosen from the group consisting of acetates, benzoates, salicylates, ester 610, caprylic / capric / succinic triglycerides, stearates and isostearates, ethylhexanoates, palmitates, isononanoates, oieates, neopentanoates, myristates and the like, whose chains are free from free and / or reactive groups or functions
- sulforaphane is a natural, extracted or synthetic sulforaphane. Synthetic sulforaphane is more accessible in terms of quantity and purity.
- the sulforaphane used may be racemic or optically pure.
- said cosmetically and / or pharmaceutically acceptable excipient is a methylpolysiloxane.
- said composition is a pharmaceutical composition such as a sunscreen product, a product against hyperpigmentation, a depigmenting product, an anti-pollution screen, a treatment product against lucite, cancer (of the skin) and the like, such as, for example, a protective agent against the effects of radiation.
- a sunscreen product such as a sunscreen product, a product against hyperpigmentation, a depigmenting product, an anti-pollution screen, a treatment product against lucite, cancer (of the skin) and the like, such as, for example, a protective agent against the effects of radiation.
- the anhydrous chain esters free from groups or free and / or reactive functions of the composition according to the invention are typically very stable esters, which do not rancid, moisturizing and healing, which constitute a good penetrating agent and regulate the production of sebum. .
- the invention also relates to a method for stabilizing a compound of general formula f in which R 1 and R 2 both represent independently of one another, an alkyl, aryl, arylalkyl group optionally substituted with one or more linear or branched groups, optionally cyclic, optionally bearing one or more heteroatoms.
- said anhydrous ester with chains free of free and / or reactive groups or functions is chosen from the group consisting of acetates, benzoates, salicylates, ester 610, caprylic / capric / succinic triglycerides, stearates. and isostearates, ethylhexanoates, palmitates, isononanoates, oieates, neopentanoates, myristates and the like.
- said ester is chosen from acetates (benzyl acetate, linalyl acetate, topcopheryl acetate, etc.), benzoates (benzyl benzoate, alkyl benzoate, etc.). salicylates (benzyl, methyl, ethyl, amyl, etc.), ester 610, caprylic / capric / succinic triglycerides, stearates and isostearates (isostearyl isostearate, cetearyl stearate, etc.), ethylhexanoates , palmitates (octyl palmitate, ...), isononanoates, oieates, neopentanoates (isostearyl neopentanoate, ...), myristates, ...
- sulforaphane is a natural extracted or synthetic sulforaphane.
- the process further comprises a step of mixing said compound of general formula (I) stabilized with at least one cosmetically and pharmaceutically acceptable excipient.
- said excipient is chosen from the group of methylpolysiloxanes and their derivatives, preferably in liquid, oily form, of gel, cream, etc.
- the present invention also relates to a use of an anhydrous ester with chains free of groups and free and / or reactive functions cosmetically and pharmaceutically acceptable for stabilizing a compound of general formula I in which and R 2 both represent, independently of one of the other, an alkyl, aryl, arylalkyl group, optionally substituted with one or more linear or branched groups, optionally cyclic, optionally bearing one or more heteroatoms.
- a dosage formulation typically a sunscreen product, a hyperpigmentation product, a depigmenting product, an anti-polishing screen, a product against lucite, cancers (of the skin) and the like.
- said anhydrous ester whose chains are free from free and / or reactive groups or functions is chosen from the group consisting of acetates, benzoates, salicylates, ester 610, caprylic / capric / succinic triglycerides, stearates and isostearates, ethylhexanoates, palmitates, isononanoates, oleates, neopentanoates, myristates and the like.
- acetates benzoates, salicylates, ester 610, caprylic / capric / succinic triglycerides, stearates and isostearates, ethylhexanoates, palmitates, isononanoates, oleates, neopentanoates, myristates and the like.
- Figure 1 illustrates the degradation of sulforaphane at 250 ° C.
- Figure 2 illustrates the stability of sulforaphane alone, in water and in alcohol at 40 ° C.
- Figure 3 illustrates the stability in a hydro-alcoholic antioxidant medium as a function of temperature.
- Figure 4 illustrates the stability of sulforaphane in a medium containing phospholipids.
- Figure 5 illustrates the stability of sulforaphane in various vegetable oils, examples of fatty alcohols or nucleophilic functions.
- FIG. 6 illustrates the stability of sulforaphane in an anhydrous ester with chains free of groups and functions which are free and / or reactive cosmetically and pharmaceutically acceptable according to the invention.
- Figure 7 illustrates the stability of sulforaphane in tocopheryl acetate.
- FIG. 8 illustrates the stability of sulforaphane in a galenic composition according to the invention
- Figure 9 illustrates the stability of sulforaphane in triethylpropane triisostearate and in coca caprylate-caprate.
- Figure 10 illustrates the stability of sulforaphane in 2-octyldodecanol (Nol 20) and in dimethyl isosorbide.
- sulforaphane The stability of sulforaphane was studied as follows: a 1% solution of sulforaphane in different media to be tested is prepared. The preparation, kept in a closed container, is then thermostated at 25 ° C, 37 ° C or 40 ° C. Kinetic monitoring is performed by the residual sulforaphane assay.
- HPLC method used is as follows:
- Chromatographic analysis (not shown) reveals that the first day is already showing a second peak close to that of sulforaphane that we identified as the coupling compound with ethanol. Degradation in ethanol at 40 ° C is followed for a shorter time because the very large difference in absorbance, as well as the similarity of the retention times between sulforaphane and the coupling derivative, adversely affect the quality of the analysis at the times the However, the trend is already very marked in the early days. The results of the residual sulforaphane content are plotted in FIG. 2.
- reaction V In an alcoholic medium (as in the presence of thiols), the intermediate formed is more stable and the reaction stops, as shown below in reaction V in the case of an alcohol.
- suiforaphane contains an isothiocyanate function
- allyl isothiocyanate is known to generate degradation products similar to those observed for suiforaphane
- the stabilization of allylisothiocyanate has been studied.
- allyl isothiocyanate commerciai is sold in stabilized form by Sigma-Aldrich using ⁇ (2,6-di-tert-butyl-4-methylphenol), known for its antioxidant properties.
- Phospholipids do not exhibit nucleophilic function as such and constitute a matrix sometimes used in cosmetics.
- sulforaphane 1% of sulforaphane per ml of solution containing disphospholipids, such as phosal®, was placed. The preparation, kept in a closed container is then thermostated at 40 ° C. Kinetic monitoring is performed by assaying residual sulforaphane:
- HPLC method used is as follows:
- the degradation is very fast here, more than 40% degradation in less than 3 days.
- this product actually contains a certain amount of ethanol. This could explain the rapid formation of a compound that we have shown to be the coupling product between ethanol and sulforaphane isothiocyanate. However, degradation is faster here than in ethanol alone.
- Jojoba oil contains monounsaturated fatty acid derivatives that are free of fatty alcohol.
- Sulforaphane 1% (w / w) solutions were prepared in jojoba, argan and rose hip oils (plant extract). The degradation was then kinetically monitored using naphthalene as the external reference as above. As can be seen in Figure 5, the potential stabilization is quite disappointing, although the degradation is slower than in previous environments.
- the solubility of sulforaphane in oils is limited, about 0.5% (w / w) in jojoba oil; 2% in argan oil and 3.5% in rose hip oil.
- the degradation observed (see Figure 5) remains too important to allow commercial use. In addition, since these are complex natural products, i! There is quality variability between suppliers and between lots.
- esters usually used in cosmetics and available without reactive groups such as ester 610, methyte salicylate or isoamyl salicylate.
- the observed degradation is negligible and makes it possible to conclude that the matrix of choice which makes it possible to use sulforaphane in a galenic composition consists mainly of anhydrous chain esters without reactive groups or functions. or free compatible with the cosmetic and pharmaceutical applications envisaged. These compounds make it possible to combine solubility (> 6% (m / m)) and stability.
- Tocopheryl acetate has the following formula: As can be seen, tocopheryl acetate does not exhibit free nucleophilic function and is a matrix applicable in cosmetics.
- the degradation was then kinetically monitored at 40 ° C using naphthalene as external reference.
- the observed degradation is negligible and makes it possible to conclude that the matrix of choice which allows the use of sulforaphane in a galenic composition is consisting mainly of pure and anhydrous esters compatible with the cosmetic and pharmaceutical applications envisaged. These compounds make it possible to combine solubility (> 6% (m / m)) and stability.
- Example 5 Cosmetic formulation based on sulforaphane. 2% (w / w) solutions of sulforaphane were prepared in a mixture of isoamyl salicylate, capric / capric triglyceride and a silicone derivative (decamethylcyclopentacyloxane, for example). It was observed that the mixture of the 3 compounds made it possible to obtain the solubilization of sulforaphane at 2%, a good penetration in the skin, the stability of the asset and a soft and pleasant texture during the application. Stability was monitored over 6 months at 40 ° C. No significant degradation is observed ( ⁇ 3 to 5% / variability of the HPLC method used).
- a fragrance may be considered to cover the unpleasant but non-persistent smell of the asset.
- it may also be chosen from the family of esters which are numerous to have pleasant fragrant properties (examples: manzanate, dihydrofloralate, cyclohexylethyl acetate, etc.)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013520123A JP2013531052A (ja) | 2010-07-23 | 2011-07-19 | スルフォラファンの安定化 |
US13/811,619 US9254331B2 (en) | 2010-07-23 | 2011-07-19 | Sulforaphane stabilization |
EP11736333.3A EP2595605A1 (fr) | 2010-07-23 | 2011-07-19 | Stabilisation du sulforaphane |
AU2011281653A AU2011281653B2 (en) | 2010-07-23 | 2011-07-19 | Sulforaphane stabilization |
CN201180035952.1A CN103079545B (zh) | 2010-07-23 | 2011-07-19 | 萝卜硫烷的稳定化 |
KR1020137003899A KR20130041947A (ko) | 2010-07-23 | 2011-07-19 | 설포라판 안정화 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE2010/0462A BE1019434A3 (fr) | 2010-07-23 | 2010-07-23 | Stabilisation du sulforaphane. |
BE2010/0462 | 2010-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012010587A1 true WO2012010587A1 (fr) | 2012-01-26 |
Family
ID=43806742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/062329 WO2012010587A1 (fr) | 2010-07-23 | 2011-07-19 | Stabilisation du sulforaphane |
Country Status (8)
Country | Link |
---|---|
US (1) | US9254331B2 (fr) |
EP (1) | EP2595605A1 (fr) |
JP (1) | JP2013531052A (fr) |
CN (1) | CN103079545B (fr) |
AU (1) | AU2011281653B2 (fr) |
BE (1) | BE1019434A3 (fr) |
TW (1) | TW201208673A (fr) |
WO (1) | WO2012010587A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107162947A (zh) * | 2017-06-15 | 2017-09-15 | 重庆大学 | 一种制备稳定化莱菔素的方法 |
WO2021214188A1 (fr) * | 2020-04-23 | 2021-10-28 | Vio Chemicals Ag | Compositions pour stabiliser un isothiocyanate |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11279674B2 (en) | 2011-01-03 | 2022-03-22 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
US8933119B2 (en) | 2011-01-03 | 2015-01-13 | The William M. Yarbrough Foundation | Method for treating phytophotodermatitis |
US11407713B2 (en) | 2011-01-03 | 2022-08-09 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US10647668B2 (en) | 2011-01-03 | 2020-05-12 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
US10308599B2 (en) | 2011-01-03 | 2019-06-04 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US10273205B2 (en) | 2011-01-03 | 2019-04-30 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms |
US10640464B2 (en) | 2011-01-03 | 2020-05-05 | The William M. Yarbrough Foundation | Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US8865765B2 (en) | 2011-01-12 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating eczema |
US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
US8865772B2 (en) | 2012-07-26 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating skin cancer |
US9839621B2 (en) | 2012-07-26 | 2017-12-12 | The William M. Yarbrough Foundation | Method for treating bladder cancer |
US9949943B2 (en) | 2012-07-26 | 2018-04-24 | The William M. Yarbrough Foundation | Method for treating neurodegenerative diseases |
US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
US10080734B2 (en) | 2012-07-26 | 2018-09-25 | The William M. Yarbrough Foundation | Method for treating autism and other neurodevelopmental disorders |
US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
KR101729913B1 (ko) * | 2014-04-14 | 2017-04-25 | 주식회사 비케이바이오 | 설포라판 함량이 증가된 브로콜리의 제조방법 및 그로부터 제조된 브로콜리의 이용 |
CN104720072A (zh) * | 2015-02-15 | 2015-06-24 | 北京化工大学 | 提高莱菔素稳定性的方法 |
CN107739324A (zh) * | 2017-09-11 | 2018-02-27 | 重庆大学 | 一种制备稳定化莱菔素液体制剂的方法 |
JP2020534272A (ja) * | 2017-09-15 | 2020-11-26 | タイム,インコーポレーテッド | 経皮製剤 |
CN111012773A (zh) * | 2019-12-09 | 2020-04-17 | 浙江工业大学 | 萝卜硫烷的新用途及包含其的药物组合物 |
CN111983099A (zh) * | 2020-09-01 | 2020-11-24 | 山东省农业科学院农业质量标准与检测技术研究所 | 一种hplc法测定十字花科蔬菜中萝卜硫素和莱菔素的方法 |
WO2023133494A2 (fr) * | 2022-01-06 | 2023-07-13 | Brassica Protection Products Llc | Produits d'isothiocyanate à base d'huile et processus de préparation de produits d'isothiocyanate à base d'huile |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411986A (en) * | 1993-03-12 | 1995-05-02 | The Johns Hopkins University | Chemoprotective isothiocyanates |
FR2804318A1 (fr) | 2000-01-31 | 2001-08-03 | Serobiologiques Lab Sa | Produits de protection solaire |
WO2002015722A2 (fr) | 2000-08-21 | 2002-02-28 | Fahey Jed W | Traitement de l'helicobacter au moyen d'isothiocyanates |
FR2820036A1 (fr) * | 2001-01-26 | 2002-08-02 | L M D | Utilisation d'un isothiocyanate, d'un thiocyanate ou de leur melange en tant que depigmentant |
FR2888235A1 (fr) | 2005-07-07 | 2007-01-12 | Nutrinov Sa | Procede d'extraction de sulforaphane a partir de broyat de crucifere contenant de la glucoraphanine |
WO2008007728A1 (fr) | 2006-07-13 | 2008-01-17 | Kaneka Corporation | Préparation orale contenue dans une structure à membrane lipidique, et agent contre la fatigue comprenant une coenzyme comme ingrédient actif |
US20080176942A1 (en) * | 2007-01-23 | 2008-07-24 | Pharmagra Labs, Inc. | Stabilized sulforaphane |
EP2163238A2 (fr) | 2008-09-15 | 2010-03-17 | Henkel AG & Co. KGaA | Composition d'éclaircissement de la peau comprenant du sulforaphane ou du sulforaphene ou leur dérivés |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020063914A (ko) * | 1999-12-20 | 2002-08-05 | 코니스 프랑스, 에스.에이. | 화장용 및/또는 약학용 제제 |
FR2820035B1 (fr) | 2001-01-26 | 2003-05-02 | Oreal | Composition reductrice pour le traitement des matieres keratiniques comprenant un poly (vinyllactame) cationique |
WO2006065736A2 (fr) * | 2004-12-14 | 2006-06-22 | Johns Hopkins University | Procede d'extraction sous forme d'huile d'isothiocyanates de vegetaux contenant des glucosinolates, et procedes de preparation de produits a l'aide d'huile contenant des isothiocyanates extraits de vegetaux contenant des glucosinolates |
CN101120948A (zh) * | 2006-08-08 | 2008-02-13 | 普文英 | 一种具有化学保护、癌症预防和治疗用途的化合物组合物 |
DE102008035834A1 (de) | 2008-07-31 | 2010-02-04 | Coty Prestige Lancaster Group Gmbh | Verfahren zur Herstellung von Liposomkomplexen mit unterschiedlichen Wirkstoffen und damit hergestellte Produkte, insbesondere kosmetische Produkte |
TW201029585A (en) * | 2008-12-24 | 2010-08-16 | House Foods Corp | Method for inhibiting decomposition or degradation of lipophilic component in the presence of water |
-
2010
- 2010-07-23 BE BE2010/0462A patent/BE1019434A3/fr active
-
2011
- 2011-07-19 CN CN201180035952.1A patent/CN103079545B/zh not_active Expired - Fee Related
- 2011-07-19 US US13/811,619 patent/US9254331B2/en not_active Expired - Fee Related
- 2011-07-19 JP JP2013520123A patent/JP2013531052A/ja active Pending
- 2011-07-19 WO PCT/EP2011/062329 patent/WO2012010587A1/fr active Application Filing
- 2011-07-19 EP EP11736333.3A patent/EP2595605A1/fr not_active Withdrawn
- 2011-07-19 AU AU2011281653A patent/AU2011281653B2/en not_active Ceased
- 2011-07-21 TW TW100125786A patent/TW201208673A/zh unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411986A (en) * | 1993-03-12 | 1995-05-02 | The Johns Hopkins University | Chemoprotective isothiocyanates |
FR2804318A1 (fr) | 2000-01-31 | 2001-08-03 | Serobiologiques Lab Sa | Produits de protection solaire |
WO2002015722A2 (fr) | 2000-08-21 | 2002-02-28 | Fahey Jed W | Traitement de l'helicobacter au moyen d'isothiocyanates |
FR2820036A1 (fr) * | 2001-01-26 | 2002-08-02 | L M D | Utilisation d'un isothiocyanate, d'un thiocyanate ou de leur melange en tant que depigmentant |
FR2888235A1 (fr) | 2005-07-07 | 2007-01-12 | Nutrinov Sa | Procede d'extraction de sulforaphane a partir de broyat de crucifere contenant de la glucoraphanine |
WO2008007728A1 (fr) | 2006-07-13 | 2008-01-17 | Kaneka Corporation | Préparation orale contenue dans une structure à membrane lipidique, et agent contre la fatigue comprenant une coenzyme comme ingrédient actif |
US20080176942A1 (en) * | 2007-01-23 | 2008-07-24 | Pharmagra Labs, Inc. | Stabilized sulforaphane |
EP2120969A1 (fr) | 2007-01-23 | 2009-11-25 | Pharmagra Labs, Inc. | Sulforaphane stabilisé |
EP2163238A2 (fr) | 2008-09-15 | 2010-03-17 | Henkel AG & Co. KGaA | Composition d'éclaircissement de la peau comprenant du sulforaphane ou du sulforaphene ou leur dérivés |
Non-Patent Citations (1)
Title |
---|
See also references of EP2595605A1 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107162947A (zh) * | 2017-06-15 | 2017-09-15 | 重庆大学 | 一种制备稳定化莱菔素的方法 |
WO2021214188A1 (fr) * | 2020-04-23 | 2021-10-28 | Vio Chemicals Ag | Compositions pour stabiliser un isothiocyanate |
Also Published As
Publication number | Publication date |
---|---|
EP2595605A1 (fr) | 2013-05-29 |
CN103079545B (zh) | 2015-12-02 |
CN103079545A (zh) | 2013-05-01 |
JP2013531052A (ja) | 2013-08-01 |
AU2011281653A1 (en) | 2013-01-24 |
US9254331B2 (en) | 2016-02-09 |
US20130143963A1 (en) | 2013-06-06 |
AU2011281653B2 (en) | 2016-01-28 |
TW201208673A (en) | 2012-03-01 |
BE1019434A3 (fr) | 2012-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2595605A1 (fr) | Stabilisation du sulforaphane | |
EP1765356B1 (fr) | Composition sous forme de spray comprenant une association de calcitriol et de propionate de clobetasol, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile | |
EP1758588B1 (fr) | Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises. | |
EP0953338A1 (fr) | Dispositif de conditionnement d'un produit | |
EP3714865B1 (fr) | Composition cosmetique solaire a haute teneur en filtres solaires derives de triazine | |
EP3818973B1 (fr) | Composition solaire resistante a l'eau a haute teneur de triazines | |
WO2023281224A1 (fr) | Composition cosmetique solaire contenant des acides amines analogues de la mycosporine | |
WO2005063194A2 (fr) | Procede d'innoformulation d'une base galenique biocompatible | |
FR3001137A1 (fr) | Emulsion eau-dans-huile cosmetique ou dermatologique comprenant une merocyanine et au moins un polymere emulsionnant du type ester d'acide gras et de glycol polyoxyalkylene | |
EP3466419B1 (fr) | Utilisation du trimethoxybenzyl acetylsinapate, avantageusement en combinaison avec au moins un filtre solaire, pour la protection de la peau | |
FR3015896A1 (fr) | Solubilisation de filtres uv | |
EP1282394B1 (fr) | Utilisation de derives de l'acide n,n'-dibenzyl ethylene diamine n,n'-diacetique comme agent anti-pollution | |
EP4262706A1 (fr) | Bactériorubérines glycosylées et leurs applications industrielles | |
EP3854377A1 (fr) | Composition comprenant de l'acide hyaluronique et un polyol ou de carboxyméthylcellulose | |
KR20130041947A (ko) | 설포라판 안정화 | |
EP3263092A1 (fr) | Formulation cosmetique comprenant un precurseur liposoluble de silanol et un un ester d'acide gras de vitamine c | |
WO2023041869A1 (fr) | Utilisation d'ester gras en tant qu'agent solubilisant de filtre uv liposoluble | |
FR3128881A1 (fr) | Composition solaire comprenant des filtres UV organiques et des copolymères huileux respectueux de l’environnement | |
FR3116437A1 (fr) | Composition pour le blanchiment et/ou l'éclaircissement des matières kératineuses | |
FR3130594A1 (fr) | Composition cosmétique ou dermatologique comprenant une mérocyanine et du resvératrol et/ou un dérivé de resvératrol | |
FR3124081A1 (fr) | Composition cosmétique comprenant au moins une huile polaire, un polyol et au moins un actif hydrophile | |
FR3130597A1 (fr) | Composition cosmétique ou dermatologique comprenant une mérocyanine et au moins un diol comportant de 4 à 7 atomes de carbone | |
FR3130599A1 (fr) | Composition cosmétique ou dermatologique comprenant une mérocyanine et une gamma-butyrolactone et/ou un gamma-butyrolactame | |
FR3132637A1 (fr) | Composition cosmétique ou dermatologique comprenant une mérocyanine et un complexe polyionique | |
FR3060356A1 (fr) | Composition comprenant la baicaline et/ou l’un de ses derives et un polyurethane associatif non ionique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180035952.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11736333 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013520123 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011281653 Country of ref document: AU Date of ref document: 20110719 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13811619 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20137003899 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2011736333 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011736333 Country of ref document: EP |